ClinConnect ClinConnect Logo
Search / Trial NCT06878729

Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI

Launched by NATIONAL INSTITUTE OF CARDIOLOGY, WARSAW, POLAND · Mar 10, 2025

Trial Information

Current as of May 09, 2025

Not yet recruiting

Keywords

Coronary Artery Disease Percutaneous Coronary Intervention Coronary Chronic Total Occlusion Antegrade Dissection And Re Entry Retrograde Strategy

ClinConnect Summary

The ADRENALINE trial is a research study that aims to compare two different methods for treating a specific type of heart problem called chronic total occlusion (CTO), where a coronary artery is completely blocked. The two methods being compared are called antegrade dissection and re-entry (ADR) and retrograde strategy. Researchers want to find out which method is quicker, safer, and more effective, and how these procedures affect the stress levels of the doctors performing them. They will also look at whether the retrograde method leads to more heart damage compared to ADR.

To participate in this trial, individuals must be aged 65 or older and have certain heart conditions, such as chest pain or documented heart issues that require treatment for a difficult blockage in their coronary arteries. Participants will undergo various tests before and after the procedure to monitor their heart health and overall well-being. It’s important to know that potential participants will need to give their consent and that certain health conditions, like severe heart disease or recent heart attack, may disqualify them from the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and/or documented ischemia or viability)
  • at least difficult native CTO lesion with J-CTO difficulty score ≥2 points on invasive angiography
  • angiographic suitability for both ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
  • informed consent for participation in the study
  • Exclusion Criteria:
  • \<18 years of age
  • acute myocardial infarction
  • cardiogenic shock
  • severe valvular disease
  • estimated life expectancy \<1 year
  • contraindication to PCI
  • contrast allergy
  • positive pregnancy test or breast-feeding
  • native CTO lesion with easy or intermediate difficulty score on invasive angiography (J-CTO score \<2 points)
  • lack of angiographic equipoise between the ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators

About National Institute Of Cardiology, Warsaw, Poland

The National Institute of Cardiology in Warsaw, Poland, is a leading research institution dedicated to advancing the understanding and treatment of cardiovascular diseases. Renowned for its commitment to innovative clinical research, the Institute focuses on improving patient outcomes through comprehensive studies that encompass prevention, diagnosis, and therapeutic strategies. With a multidisciplinary team of experts and state-of-the-art facilities, the National Institute of Cardiology plays a pivotal role in contributing to global cardiovascular knowledge and enhancing clinical practices in the field.

Locations

Warsaw, , Poland

Patients applied

0 patients applied

Trial Officials

Maksymilian Opolski

Principal Investigator

National Institute of Cardiology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported